Clinical trial
Study of Rebamipide Eye Drops to Treat Dry Eye
NCT00201955 · Otsuka Pharmaceutical Development & Commercialization, Inc., Industry · Completed
Key facts
| NCT number | NCT00201955 |
|---|---|
| Title | Study of Rebamipide Eye Drops to Treat Dry Eye |
| Official title | Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye: A Multicenter, Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, 26 Week Study |
| Lead sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc., Industry |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Keratoconjunctivitis Sicca |
| Intervention type | Drug |
| Interventions | Rebamipide |
| Enrollment | 740 |
| Start date | May 1, 2004 |
| Completion | Jul 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Nov 2, 2006 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: